We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 228

Federal court affirms principle of claim differentiation in evaluating utility
  • Gowling Lafleur Henderson LLP
  • Canada
  • June 30 2015

Justice O'Reilly of the Federal Court has rejected Teva's allegations of invalidity regarding Novartis's patent covering its iron chelator product


Federal Court of Appeal questions patent law principles
  • Gowling Lafleur Henderson LLP
  • Canada
  • June 17 2015

In Cobalt v Bayer (2015 FCA 116) the Federal Court of Appeal explicitly called into question two central principles of Canadian patent law: the


FCA confirms that no disclosure of factual basis or line of reasoning is required for sound prediction when they would be self-evident to the skilled person
  • Gowling Lafleur Henderson LLP
  • Canada
  • June 11 2015

In reasons dated June 3, 2015, the Federal Court of Appeal (FCA) affirmed a decision of Justice O'Reilly (2014 FC 567) dismissing Apotex's


Post Amazon.com how the Canadian patent Appeal Board has dealt with patenteligibility of computer-implemented subject matter
  • Gowling Lafleur Henderson LLP
  • Canada
  • June 4 2015

In November 2011, the Federal Court of Appeal in Amazon.com v. Canada (2011 FCA 328) sought to clarify Canadian law relating to patentability of


Federal Court of Appeal suggests need for Supreme Court to consider standard of review on claims construction and patentability of methods of medical treatment
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 12 2015

The Federal Court of Appeal (FCA) in Cobalt v. Bayer has explicitly called into question two central principles of Canadian patent law: the standard


Apotex denied claim for innovator's profits following PM(NOC) litigation
  • Gowling Lafleur Henderson LLP
  • Canada
  • May 7 2015

The ongoing quest by generic pharmaceutical companies for the disgorgement of innovator profits following litigation under the PM(NOC) Regulations


La Cour suprême du Canada rejette le premier appel entendu visant une réclamation en dommages-intérêts au titre de l’article 8
  • Gowling Lafleur Henderson LLP
  • Canada
  • April 29 2015

Le 20 avril 2015, la Cour suprême du Canada a rejeté l’appel de Sanofi-Aventis à l’égard d’une action intentée par Apotex en vue de réclamer des


Supreme Court of Canada dismisses first section 8 damages appeal
  • Gowling Lafleur Henderson LLP
  • Canada
  • April 28 2015

On April 20, 2015, the Supreme Court of Canada dismissed Sanofi-Aventis' appeal concerning a claim by Apotex for section 8 damages under the Patented


Applications for leave to appeal dismissed - 23 April 2015
  • Gowling Lafleur Henderson LLP
  • Canada
  • April 23 2015

On appeal from the Court of Appeal for British Columbia. In 2007, the applicant was charged with, and convicted of, sexual assault after having


Canadian patent law: 2014 year in review
  • Gowling Lafleur Henderson LLP
  • Canada
  • March 18 2015

This article summarises noteworthy Canadian patent law decisions and developments from 2014. Court of Appeal addresses patent utility in Celebrex The